Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Rivaroxaban-Day'

Rivaroxaban-Day published presentations and documents on DocSlides.

Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease:
Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease:
by giovanna-bartolotta
Rivaroxaban Plus Aspirin in Patients With and Wit...
A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban
A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban
by celsa-spraggs
Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...
Rivaroxaban or Aspirin for Extended Treatment of Venous Thr
Rivaroxaban or Aspirin for Extended Treatment of Venous Thr
by yoshiko-marsland
(EINSTEIN CHOICE). Ryan Sparks, . PharmD. , BCPS....
Reversing Course: Managing Anticoagulation and Antiplatelet Bleeding
Reversing Course: Managing Anticoagulation and Antiplatelet Bleeding
by kyle585
Paul P. . Dobesh. , . Pharm.D. , FCCP, BCPS, BCCP....
Review on NOACs Studies Dr.
Review on NOACs Studies Dr.
by BlessedBeyondMeasure
Kourosh. . Sadeghi. Tehran University of medical ...
MAGELLAN Primary efficacy endpoint at 10 days (DVT, symptomatic PE,
MAGELLAN Primary efficacy endpoint at 10 days (DVT, symptomatic PE,
by HoneyBun
VTE death. ) for . rivaroxaban. vs. . enoxaparin....
X- VeRT CV death, stroke/TIA, non-CNS systemic embolism, or MI: 0.51% of the
X- VeRT CV death, stroke/TIA, non-CNS systemic embolism, or MI: 0.51% of the
by LittleMissPerfect
rivaroxaban. group vs. 1.02% of the vitamin K ant...
Thromboembolic protocols
Thromboembolic protocols
by cecilia
& safe anticoagulant prescribing. July 2020. D...
Rivaroxaban in stable peripheral or carotid artery disease
Rivaroxaban in stable peripheral or carotid artery disease
by basidell
Sonia Anand, on . behalf of the COMPASS Steering C...
Ima A. Kusuma , MD, FIHA
Ima A. Kusuma , MD, FIHA
by hirook
“JIH. ” Hospital, Yogyakarta, Indonesia. The U...
Dr. Phil Wells on behalf of the EINSTEIN CHOICE Steering Committee and Investigators
Dr. Phil Wells on behalf of the EINSTEIN CHOICE Steering Committee and Investigators
by yoshiko-marsland
Dr. Phil Wells on behalf of the EINSTEIN CHOICE ...
CAD/PAD in Primary Care CV Risk in Stable Outpatients
CAD/PAD in Primary Care CV Risk in Stable Outpatients
by stefany-barnette
Stratified by Baseline CV Risk Category. Aspirin ...
A New Era in Anticoagulation Management
A New Era in Anticoagulation Management
by alexa-scheidler
Allyson Sarigianis, Pharm.D.. October 19, 2013. O...
Stroke, Bleeding, and
Stroke, Bleeding, and
by lois-ondreau
Mortality Risks . in . Elderly Medicare Beneficia...
A Multicenter Randomized Trial Evaluating Clinically Signif
A Multicenter Randomized Trial Evaluating Clinically Signif
by giovanna-bartolotta
Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...
New Oral Anticoagulant
New Oral Anticoagulant
by mitsue-stanley
R2 Patcharee Seesongsom. R2 . Sirada. . Phoja...
R eal-world
R eal-world
by liane-varnes
EVI. dence. on . S. troke prevention . I. n pati...
A Multicenter Randomized Trial Evaluating Clinically Signif
A Multicenter Randomized Trial Evaluating Clinically Signif
by ellena-manuel
Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...
A New Era in Anticoagulation Management
A New Era in Anticoagulation Management
by debby-jeon
Allyson Sarigianis, Pharm.D.. October 19, 2013. O...
Novel Oral Anticoagulants
Novel Oral Anticoagulants
by natalia-silvester
(. N. OAC). Dan . Moellentin. , . PharmD. , BCPS,...
Recent ACS: STEMI, NSTEMI, UA
Recent ACS: STEMI, NSTEMI, UA
by danika-pritchard
Stabilized 1-7 Days Post-Index Event. Exclusions:...
Anisah Ahmad Pharmacist
Anisah Ahmad Pharmacist
by genevieve
01904 72(4328). Anticoagulants . Warfarin . Novel ...
Direct oral anticoagulant (DOAC) haemorrhage protocol
Direct oral anticoagulant (DOAC) haemorrhage protocol
by brianna
1. Contact haematologist on call. , document DOAC ...
Abbreviations: AF: atrial fibrillation, ACS: acute coronary syndrome, BD: twice daily, CAD: corona
Abbreviations: AF: atrial fibrillation, ACS: acute coronary syndrome, BD: twice daily, CAD: corona
by holly
CrCl. : creatinine clearance, CTO: chronic total o...
28 th August 2022 Ganesan Karthikeyan, Stuart Connolly*,
28 th August 2022 Ganesan Karthikeyan, Stuart Connolly*,
by dorothy
Mpiko. . Ntsekhe. , Bongani . Mayosi. * and Salim...
COMPASS: Show Us the Way for Medical Management of PAD
COMPASS: Show Us the Way for Medical Management of PAD
by miller
Clinical Associate Professor of Medicine. SSM Heal...
DentalUpdateNovember 2015A New Generation of Antiplatelet and Anticoag
DentalUpdateNovember 2015A New Generation of Antiplatelet and Anticoag
by cecilia
Steven Johnston, BDS, MSc, MFDS RCS(Ed), Dental Of...
P erioperative management of anticoagulated geriatric patients with
P erioperative management of anticoagulated geriatric patients with
by TinyTeddy
hip fractures. Dr Linda Xu . linda.xu@health.nsw.g...
Atrial Fibrilation (Anticoagulation)
Atrial Fibrilation (Anticoagulation)
by CupcakeCutie
M.A . Akbarzadeh. MD. Assistant . professor of . ...
Management of Anticoagulant-Related Major Bleeding: Clinical Updates and Best Practices for Health-
Management of Anticoagulant-Related Major Bleeding: Clinical Updates and Best Practices for Health-
by melanie
Provided by ProCE, LLC and supported by an educati...
New (Direct)Oral anti-coagulants in the treatment of VTE
New (Direct)Oral anti-coagulants in the treatment of VTE
by ariel
Dr NA Smith - Haematology Dept. Heart of England...
Spotlight Case New Oral Anticoagulants
Spotlight Case New Oral Anticoagulants
by skylar
This presentation is based on the . December 2013....
The thick and thin of it: Reviewing Anticoagulant Options
The thick and thin of it: Reviewing Anticoagulant Options
by oneill
Lanae Fox, . PharmD. , BCPS. I have no financial d...
Safe and Effective Use of Novel Oral Anticoagulants for Atrial Fibrillation: What You Need to Know
Safe and Effective Use of Novel Oral Anticoagulants for Atrial Fibrillation: What You Need to Know
by dsuser1
Christopher Granger, . MD. Sean Pokorney, MD. . D...
Bleeding and cancer risk in patients with vascular
Bleeding and cancer risk in patients with vascular
by danika-pritchard
Bleeding and cancer risk in patients with vascul...
Anticoagulation and Thrombosis Management
Anticoagulation and Thrombosis Management
by pasty-toler
Anticoagulation and Thrombosis Management A Revie...
Pharmacology of Anticoagulants
Pharmacology of Anticoagulants
by conchita-marotz
Nathan Culver, . PharmD. , BCPS. anticoagulant Me...
New Oral Anticoagulants: A Review
New Oral Anticoagulants: A Review
by phoebe-click
Babak Moini, MD. Veterans Affairs Hospital. Noon ...
POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF
POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF
by phoebe-click
NOACS IN AF. Where Do We Stand With NOACs in AF ...
Sandy Bartlett, PhD, PharmD
Sandy Bartlett, PhD, PharmD
by mitsue-stanley
, . BCPS, BCCCP. Associate Professor | Department...